TransCode Therapeutics Appoints Scientific Advisory Board Chair, Partners with Michigan State University to Advance RNA-Based Cancer Therapies
TransCode Therapeutics announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with Michigan State University to advance its RNA-based therapeutic pipeline, including lead candidate TTX-MC138.
TransCode Therapeutics (NASDAQ: RNAZ) has named Dr. Anna Moore as Chair of its Scientific Advisory Board and entered into a sponsored research agreement with Michigan State University, signaling a strategic push to accelerate development of its RNA-based cancer treatments. The move underscores the company's focus on tackling high-risk and advanced cancers through innovative immuno-oncology and RNA therapeutics.
Dr. Moore, a respected figure in molecular imaging and nanomedicine, will provide strategic guidance on TransCode's research and development efforts. The sponsored research agreement with Michigan State University is expected to support the development of TransCode's lead candidate, TTX-MC138, including evaluation in combination with other therapies. This partnership could be pivotal in advancing the candidate's clinical trajectory, particularly for treating metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis.
TransCode Therapeutics is a clinical-stage company pioneering RNA-based therapies for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors with microRNA-10b overexpression. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system against cancer cells. The appointment of Dr. Moore and the collaboration with Michigan State University are expected to bolster these efforts.
The news is significant for investors and the broader oncology community, as it highlights TransCode's commitment to advancing its pipeline through high-level scientific expertise and academic partnerships. The company's focus on RNA therapeutics places it at the forefront of a rapidly evolving field, with potential implications for treating some of the most challenging cancers. For more details, the full press release is available at https://ibn.fm/NA2NH.